A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

February 2, 2017

Primary Completion Date

November 23, 2021

Study Completion Date

November 23, 2021

Conditions
Advanced Cancer
Interventions
BIOLOGICAL

Nivolumab

Specified Dose on Specified Days

BIOLOGICAL

Ipilimumab

Specified Dose on Specified Days

BIOLOGICAL

Relatlimab

Specified Dose on Specified Days

DRUG

BMS-986205

Specified Dose on Specified Days

DRUG

BMS-813160

Specified Dose on Specified Days

Trial Locations (32)

2145

Local Institution - 0032, Westmead

3165

Monash Medical Centre Clayton, Bentleigh

4010

Local Institution - 0044, Linz

10065

Local Institution - 0005, New York

14263

Roswell Park Cancer Institute, Buffalo

18103

Local Institution - 0002, Allentown

20133

Local Institution - 0010, Milan

21287

Local Institution - 0007, Baltimore

22908

Local Institution - 0024, Charlottesville

28204

Local Institution - 0043, Charlotte

29425

Hollings Cancer Center, Charleston

30912

Local Institution - 0031, Augusta

37203

Local Institution - 0025, Nashville

43210

Local Institution - 0014, Columbus

48201

Local Institution - 0011, Detroit

52621

Local Institution, Ramat Gan

60612

Local Institution - 0006, Chicago

63110

Local Institution - 0008, St Louis

80131

Local Institution - 0012, Napoli

97239

Oregon Health & Science University, Portland

98109

University of Washington - Seattle Cancer Care Alliance, Seattle

3109601

Local Institution, Haifa

06520

Local Institution - 0037, New Haven

33612-9497

Local Institution, Tampa

02215

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

75390-8570

Ut Southwestern Medical Center, Dallas

L8V 5C2

Local Institution - 0038, Hamilton

L1G 2B9

Local Institution - 0029, Oshawa

M5G 1Z6

Local Institution - 0035, Toronto

H3T 1E2

Local Institution - 0034, Montreal

G1R 2J6

Local Institution - 0030, Québec

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02996110 - A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter